(ALAMEDA, CA) Calypte Biomedical Corporation has announced that the State Drug Administration of the People's Republic of China (PRC) has approved its HIV-1 antibody urine test. According to the Joint Nations Programme on HIV/AIDS, half a million Chinese citizens are currently infected with the HIV virus. Left unchecked, officials of the Chinese National Center for AIDS Prevention and Control (NCAIDS) estimate that the total number of HIV infections in China could reach 10 million before 2010. Earlier this year, Calypte announced that it had partnered with NCAIDS through Beijing HuaAi Science and Technology Development Co. Ltd. to distribute the HIV-1 urine test within the PRC. For more information visit www.calypte.com.
Top 7 Infection Control Today Articles of 2024: Insights and Innovations
December 30th 2024From advanced sterilization methods to combating antimicrobial resistance, Infection Control Today’s top articles of 2024 delivered actionable strategies for safer healthcare environments and improved patient outcomes.
Revolutionizing Infection Prevention: How Fewer Hand Hygiene Observations Can Boost Patient Safety
December 23rd 2024Discover how reducing hand hygiene observations from 200 to 50 per unit monthly can optimize infection preventionists' time, enhance safety culture, and improve patient outcomes.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.